
5593-20-4
- Product Name:Betamethasone Dipropionate
- Molecular Formula:C28H37FO7
- Purity:99%
- Molecular Weight:504.596
Product Details;
CasNo: 5593-20-4
Molecular Formula: C28H37FO7
Appearance: Powder
Manufacturer supply good quality Betamethasone Dipropionate 5593-20-4 with stock
- Molecular Formula:C28H37FO7
- Molecular Weight:504.596
- Appearance/Colour:Powder
- Vapor Pressure:3.97E-18mmHg at 25°C
- Melting Point:178 °C
- Refractive Index:69 ° (C=1, Dioxane)
- Boiling Point:603.2 °C at 760 mmHg
- PKA:12.87±0.70(Predicted)
- Flash Point:318.6 °C
- PSA:106.97000
- Density:1.24 g/cm3
- LogP:3.81750
Betamethasone 17,21-dipropionate(Cas 5593-20-4) Usage
Manufacturing Process |
A solution of 9α-fluoro-11β-hydroxy-16β-methyl-17α,21-(1'-ethyl-1'- ethoxymethylenedioxy)pregna-1,4-diene-3,20-dione (538 mg) in acetic acid (20 ml), containing 2 drops of water, was allowed to stand at room temperature for 5 hours. Dilution of the mixture with water gave a white solid (457 mg) which, after being filtered off and dried, was recrystallized from acetone to afford 9α-fluoro-11β,21-dihydroxy-16β-methyl-17α- propionyloxypregna-1,4-diene-3, 20-dione (361 mg), MP 230°-235°C. Bethmethasone 17-propionate (812 mg) in pyridine (10 ml) was treated with propionyl chloride (0.21 ml) at 0°C for 1 hour. Dilution with water and acidification with dilute hydrochloric acid gave the crude diester. Recrystallization from acetone-petroleum ether afforded betamethasone 17,21-dipropionate (649 mg), MP 117°C (decomposition). |
Therapeutic Function |
Glucocorticoid |
Biochem/physiol Actions |
Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity. |
Safety Profile |
Poison by subcutaneous andintraperitoneal routes. An experimental teratogen. Otherexperimental reproductive effects. When heated todecomposition it emits toxic fumes of F-. |
Definition |
Betamethasone 17,21-dipropionate is a steroid ester that is betamethasone in which the hydroxy hydrogens at positions 17 and 21 are replaced by propanoyl groups. It is used in combination with calcipotriene hydrate, a synthetic vitamin D analogue, for the topical treatment of plaque psoriasi in adult patients. |
Brand name |
Alphatrex (Savage); Diprolene (Schering). |
InChI:InChI=1/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1
5593-20-4 Relevant articles
Preparation method of betamethasone dipropionate
-
Paragraph 0009; 0044-0062, (2021/05/29)
The invention belongs to the technical f...
Preparation method of betamethasone 17 alpha-propionate
-
Paragraph 0011; 0012; 0013; 0014; 0015; 0016; 0018, (2019/08/20)
The invention provides a preparation met...
Pharmaceutical composition
-
, (2008/06/13)
A pharmaceutical composition for dermal ...
Composition for the topical treatment of poison ivy and other forms of contact dermatitis
-
, (2008/06/13)
Composition for topical administration c...
5593-20-4 Process route
-
-
5534-13-4
Betamethasone propionate

-
-
123-62-6
propionic acid anhydride

-
-
5593-20-4
betamethasone dipropionate
Conditions | Yield |
---|---|
With
dmap;
In
dichloromethane;
at 0 - 10 ℃;
Reagent/catalyst;
Solvent;
Temperature;
Inert atmosphere;
Large scale;
|
96% |
-
-
5534-13-4
Betamethasone propionate

-
-
5593-20-4
betamethasone dipropionate
Conditions | Yield |
---|---|
In
tetrahydrofuran; water;
at 50 - 80 ℃;
for 8h;
under 450.045 Torr;
|
5593-20-4 Upstream products
-
betamethasone
-
Betamethasone propionate
-
propionic acid anhydride
5593-20-4 Downstream products
-
betamethasone
-
Betamethasone propionate
-
9α-fluoro-6,11β,17α,21-tetrahydroxy-16β-methyl-1,4,6-pregnatriene-3,20-dione 6-benzoate 17,21-dipropionate
-
9α-fluoro-3,11β,17α,21-tetrahydroxy-16β-methyl-1,3,5-pregnatriene-20-one 3-benzoate 17,21-dipropionate
Relevant Products
-
para-fluoro Methylaminorex
CAS:1364933-64-1
-
Tantalum
CAS:7440-25-7
-
Brexanolone
CAS:516-54-1